Novavax asks FDA for emergency use authorization for its vaccine
Novavax on Monday submitted a request to the FDA for emergency use authorization for its COVID-19 vaccine.
Novavax uses a more traditional protein-based vaccine platform, which is different from Pfizer and Modena’s mRNA technology and Johnson & Johnson's viral vector technology.
Novavax's vaccine exposes a person to a lab-based piece of coronavirus to build immunity.
Novavax's studies -- conducted before the omicron variant -- showed an approximately 90% efficacy.
Novavax was one of the early contenders for a COVID-19 vaccine; Operation Warp Speed allocated $1.6 billion for 100 million doses if the vaccine was authorized by the FDA.
-ABC News' Eric M. Strauss